R-Zero benchmarked Arc's performance against two reference market-leading products sold into hospitals: Tru-D and UVDI 360 (formerly Clorox Optimum Pro).
Arc delivered an average dose of 250.0 mJ/cm2 in a 7-minute cycle, at a distance of 8 ft. Based on published dose-response models, we expect greater than 4 log reduction (>99.99% inactivation) for all of the challenge species that are the subject of the ongoing testing. These species are calicivirus feline, beta coronavirus (229E), MRSA, and E coli.
Arc delivered a dose 67% higher than the Tru-D device and 121% higher than the UVDI/Clorox device in a 5-minute cycle.
